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 2 
Abstract 28 
Nontyphoidal Salmonella (NTS) are among the most common aetiological agents of diarrhoeal 29 
diseases worldwide and have become the most commonly detected bacterial pathogen in children 30 
hospitalised with diarrhoea in Vietnam. Aiming to better understand the epidemiology, serovar 31 
distribution, antimicrobial resistance (AMR), and clinical manifestation of NTS gastroenteritis in 32 
Vietnam, we conducted a clinical genomics investigation of NTS isolated from diarrheal children 33 
admitted to one of three tertiary hospitals in Ho Chi Minh City. Between May 2014 and April 34 
2016, 3,166 children hospitalized with dysentery were recruited into the study; 478 (~15%) 35 
children were found to be infected with NTS by stool culture. Molecular serotyping of the 450 36 
generated genomes identified a diverse collection of serogroups (B, C1, C2-C3, D1, E1, G, I, K, 37 
N, O, Q); however, S. Typhimurium was the most predominant serovar, accounting for 41.8% 38 
(188/450) of NTS isolates. We observed a high prevalence of AMR to first line treatments 39 
recommended by WHO and more than half (53.8%, 242/450) of NTS isolates were multi-drug 40 
resistant (MDR; resistant to ≥3 antimicrobial classes). AMR gene detection positively correlated 41 
with phenotypic AMR testing, and resistance to empirical antimicrobials was associated with a 42 
significantly longer hospitalization (0.91 days, p=0.04). Our work shows that genome sequencing 43 
is a powerful epidemiological tool to characterize the serovar diversity and AMR profiles in NTS. 44 
We propose a revaluation of empirical antimicrobials for dysenteric diarrhoea and endorse the use 45 
of whole genome sequencing for sustained surveillance of NTS internationally.       46 
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 3 
Introduction 47 
With an estimated 93.8 million cases (5th-95th percentile, 61.8-131.6 million) of gastroenteritis 48 
recorded globally per annum, Nontyphoidal Salmonella (NTS) are among the most common 49 
etiological agents of diarrheal diseases worldwide. This burden disproportionally affects young 50 
children in Asia and Africa, and results in ~155,000 deaths per year (5th-95th percentile, 39,000-51 
303,000) (1, 2).  52 
 53 
The Salmonellae are a genus of Gram-negative bacteria belonging to the Enterobacteriaceae 54 
family. The genus is classified into two species: Salmonella enterica and Salmonella bongori, 55 
with S. enterica comprised of a further six subspecies (3). Salmonella enterica subsp. enterica 56 
includes >2,500 serovars, which can cause a wide range of disease in humans and animals. This 57 
extensive diversity points to the ancestral origin of this subspecies, with Salmonella being 58 
recovered from human remnants dating back >6,500 years ago (4). Infections caused by different 59 
NTS serovars can present with differing pathology, epidemiology, clinical presentations, and 60 
antimicrobial resistance (AMR) profiles. Clinically, NTS infections are usually observed as acute 61 
gastroenteritis with the onset of fever, vomiting, abdominal cramp and diarrhea (5). These 62 
symptoms are typically self-limiting and resolve within 5-7 days. Consequently, antimicrobial 63 
treatment is deemed unnecessary and is generally not recommended (6, 7).  However, 64 
salmonellosis can also result in invasive diseases (i.e. bloodstream infection) in immuno-65 
compromised patients, which has a high mortality rate (8, 9). Therefore, antimicrobials remain 66 
crucial for the treatment of some Salmonella infections, especially in high-risk patients (7, 10). 67 
Currently, the WHO guidelines for treatment of paediatric diarrhoea recommend the use of low 68 
osmolarity oral rehydration solution (ORS), zinc, and antimicrobials for all patients with bloody 69 
diarrhea, irrespective of their age (11, 12). The drug of first choice is ciprofloxacin or one of the 70 
three second-line alternatives: pivmecillinam, azithromycin, or ceftriaxone.  71 
 72 
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 73 
Vietnam has undergone rapid economic transition, with improved sanitation, accelerated 74 
urbanization and changes in the food production and supply chains. This development has been 75 
followed by a shift in the key causes of bacterial enteric infections; NTS has now become the 76 
most common bacterial etiology for children hospitalized with diarrheal illnesses (13, 14). This 77 
pattern now more closely resembles the distribution of diarrheal infections in children in high 78 
income countries (15, 16). However, despite these apparent changes in the dynamics of enteric 79 
bacteria, the epidemiology, serovar distribution, AMR, and clinical manifestation of NTS 80 
gastroenteritis have not been characterized at scale in Vietnam. The introduction of whole 81 
genome sequencing (WGS) and analysis as a routine methodology in Low- and Middle-Income 82 
Countries (LMICs), such as Vietnam, offers an opportunity for highly detailed molecular 83 
serotyping and genotyping to infer detailed epidemiological insights. In this study, we employed 84 
genomic analysis to describe some epidemiological features of the most common NTS serovars 85 
isolated from diarrheal children admitted to one of three tertiary hospitals in Ho Chi Minh City 86 
(HCMC), Vietnam. 87 
 88 
Materials and Methods 89 
Ethics approval and consent to participate 90 
This study was approved by Ethics Committees of participating local hospitals and the University 91 
of Oxford Tropical Research Ethics Committee (OxTREC No. 1045-13), as detailed previously 92 
(14). Written consent from parents or legal guardians of all participants was obtained prior to 93 
enrolment. Consent for publication was incorporated as a component of entrance into the study. 94 
 95 
Study design 96 
Fecal samples were collected from a prospective, observational, cross-sectional study in 97 
Children’s Hospital No. 1, Children’s Hospital No. 2 and the Hospital of Tropical Diseases in 98 
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HCMC, Vietnam from May 2014 to April 2016. Children (aged <16 years) hospitalized with 99 
diarrhea, defined as ≥3 passages of loose stools within 24 hours along with at least one loose stool 100 
containing blood and/or mucus were recruited into the study (12). Children were not eligible if 101 
they had suspected or confirmed intussusception at the time of enrolment. Following enrolment, a 102 
short questionnaire (requesting clinical and demographic information) was completed, and a fecal 103 
sample was collected and processed within 24 hours. All enrolled patients were provided with the 104 
routine standard of care practices, which may have included treatment with antimicrobials. 105 
 106 
Microbiological culture and antimicrobial susceptibility 107 
Fecal specimens were inoculated onto MacConkey agar (MC, Oxoid), xylose-lysine-108 
deoxycholate agar (XLD, Oxoid), and into selenite broth (Oxoid) and incubated at 37°C for 18-24 109 
hours. Presumptive Salmonella was detected based on colony morphology on XLD and MC agar, 110 
and confirmed using matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) 111 
mass spectrometry (Bruker) (12). 112 
 113 
Antimicrobial susceptibility testing was performed using the Kirby-Bauer disc diffusion method 114 
on Mueller-Hinton agar (Oxoid) for confirmed Salmonella isolates, interpreted using the updated 115 
CLSI Guidelines (17). The tested antimicrobial agents (Oxoid) included nalidixic acid (30g), 116 
ciprofloxacin (5g), trimethoprim-sulfamethoxazole (co-trimoxazole; 1.25/23.75g), ceftriaxone 117 
(30g), ceftazidime (30g), ampicillin (10g), amoxicillin-clavulanate (20/10g), azithromycin 118 
(15g), chloramphenicol (30g), gentamicin (10g), amikacin (30g) and imipenem (10g). For 119 
Salmonella spp., susceptibility to aminoglycosides in vitro does not translate into clinical 120 
effectiveness, and thus it was not reported (17). Multi-drug resistance (MDR) was defined as non-121 
susceptibility to ≥1 agent in ≥3 antimicrobial categories (14). 122 
 123 
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 6 
Whole genome sequencing and in silico Salmonella serovar typing  124 
Total genomic DNA was extracted from retrieved confirmed Salmonella specimen (N=460) using 125 
the Wizard genomic DNA extraction Kit (Promega, USA) and sent to the Wellcome Trust Sanger 126 
Institute (WTSI) for WGS using the Illumina HiSeq 2500 platform, generating paired end reads 127 
(125bp x2) (18). Raw sequences in FASTQ format were subjected to built-in quality checking 128 
pipeline at WTSI, as described previously (19), and input into Kraken (v0.10.6) for taxonomic 129 
identification by comparison to a pre-set database (20). We performed a de novo sequence 130 
assembly using Velvet v1.2.03 and VelvetOptimizer for each isolate (21), and each read set was 131 
mapped back to the corresponding assembly to improve assembly accuracy, as performed in the 132 
WTSI analysis pipeline (22). The median number of contigs and N50 statistic per assembly were 133 
44 (IQR: 30 – 56) and 370,546 (IQR: 283,058 – 576,586), indicating that the assemblies were of 134 
sufficient quality to be used for downstream genomic analyses. 135 
 136 
In silico molecular serotyping for Salmonella was performed for individual genome assembly 137 
using the Salmonella In Silico Typing Resource (SISTR) (23). The analysis was based on the 138 
Multi-Locus Sequence Typing (MLST) scheme for Salmonella, and serovar prediction was based 139 
on identification of genetic elements coding for the O (somatic) and H (flagellar) antigens. 140 
Additionally, we performed the read-based serotyping method for Salmonella (SeqSero2) for all 141 
sequenced NTS (24), and compare these outputs with those generated by SISTR.  142 
 143 
Identification of antimicrobial resistance genes 144 
AMR genes were predicted from the raw sequencing reads of each isolate using ARIBA (25) 145 
(version 0.4.1), which identifies AMR determinants by assembly and alignment. A manually 146 
curated input database of known resistance genes in FASTA format, taken from the CARD 147 
database (McMaster University; accessed on 21st March 2017), was used as the reference 148 
database. Resistance determinants were identified if they were predicted to be functional proteins 149 
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 7 
(no truncations or premature stop codons) and fit the criteria of  95% nucleotide identity and 150 
50% sequence length matching. The output from ARIBA was manually curated to generate a list 151 
of high-confidence hits of acquired AMR genes. Chromosomal mutations in the quinolone 152 
resistance determining region (QRDR) were manually detected in gyrA, gyrB, parC and parE.  153 
 154 
Correlation of susceptibility phenotypes and genotypes 155 
The presence of AMR determinants, as identified by ARIBA, indicates a non-susceptible 156 
genotype to the corresponding antimicrobial. The phenotypic nonsusceptibility to all tested 157 
antimicrobials in our Salmonella collection was compiled, with intermediate phenotypes 158 
interpreted as non-susceptible. To determine the correlation of antimicrobial susceptibility 159 
phenotypes and genotypes, we calculated the sensitivity, specificity, positive predictive value 160 
(PPV) and negative predictive value (NPV) of the presence/absence of AMR genes, using the 161 
phenotypic data as the gold standard. 162 
 163 
Demographic and clinical data analysis 164 
Clinical and demographic data were collected from all anonymized participants and processed 165 
and analyzed using Stata v11 (StataCorp, College Station, TX, USA). The growth status of 166 
participants was assessed using the WHO global database on growth and nutrition, and 167 
Prevention and Management of Obesity for Children and Adolescents-Healthcare guidelines, 168 
using the “macro” package of Stata v11 developed by WHO (26, 27). Hemoglobin concentration 169 
cut-off for anemia diagnosis was assessed using the recommended WHO guidelines (28). The 170 
demographic (age, sex, nutritional status, anemia status), clinical (diarrhea type, number of 171 
diarrhea episodes per day, hospitalization duration, outcome) and laboratory data (neutrophil 172 
count, CRP concentration) were compared among the six most abundant ST (n ≥ 20), using the 173 
Kruskal-Wallis test (continuous variables) and Chi-squared/Fisher Exact tests (categorical 174 
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 8 
variables). Resulting p-values were corrected for multiple hypothesis testing (Bonferroni 175 
correction). Data analysis and visualization were performed using R v3.6.3 (29).  176 
 177 
Availability of data and materials 178 
The raw sequence data generated from this study are available in the European Nucleotide 179 
Archive (ENA) under the project number PRJEB9121 (ERR1764086 – ERR1764359; 180 
ERR1788605 – ERR1788707; ERR1821189 – ERR1821283; ERR1837087 – ERR1837088). 181 
 182 
Results 183 
Clinical manifestations of non-typhoidal Salmonella infections 184 
Between May 2014 and April 2016, 3,166 children hospitalized with dysentery were recruited 185 
into the study (14); 478 (~15%) children were identified to be infected with NTS by stool culture. 186 
However, the bacteria were successfully retrieved and subjected to WGS for 460 cases. Three 187 
isolates failed during WGS due to low DNA yield. Subsequent quality control showed that 188 
additional seven isolates were contaminated with other bacteria (Escherichia coli, Citrobacter, 189 
Pseudomonas). Therefore, the downstream analyses were performed on 450 NTS organisms and 190 
associated metadata. More than half of these children were male (272/450; 60.3%), with the age 191 
ranging from 1 to 135 months (median 9 months, IQR 6.4-14.9 months); 22.4% (101/450) of 192 
children were <6 months of age. These children had a median of 2 days of symptoms (IQR: 2-4 193 
days) before hospitalization. One third of this population had an abnormal growth status, with 194 
22.2% (100/450) being overweighed/obese and 12.5% (56/450) being wasted/severely wasted 195 
(Table 1). Hemoglobin concentrations, according to WHO guidelines, showed that 32.9% of these 196 
children were anemic (148/450). Sixty percent (274/450) of these children were hospitalized for 197 
acute bloody diarrhea;  the remainder had mucoid diarrhea without visible blood (Table 1). 198 
Profuse diarrhea was commonly recorded with an average of 10 episodes in 24-hour period (IQR: 199 
6-10 episodes). Other symptoms, including fever (294/450, 65.3%) and vomiting (190/450, 200 
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 9 
42.2%), were also frequent. Most children (except for 25 cases) were assessed not to be 201 
dehydrated. No severe sequelae or death were recorded. 202 
 203 
The temporal distribution of Salmonella sequence types  204 
Molecular serotyping was performed on each of the 450 assembled genomes, all of which were 205 
assigned a serotype (Table 2). Serotyping results were largely consistent between the two 206 
employed methods (SISTR and SeqSero2), with mismatch in only 4 isolates (<1%). For 207 
consistency, the serotyping results presented herein were derived from the SISTR output. All but 208 
two (houtenae and salamae) NTS isolates were identified as subspecies enterica, and comprised 209 
of diverse collection of serogroups (B, C1, C2-C3, D1, E1, G, I, K, N, O, and Q). Accounting for 210 
41.8% (188/450) of isolates, S. Typhimurium was the most predominant serovar. This serovar 211 
was comprised of three sequence types (STs). More than two thirds (133/188) of these S. 212 
Typhimurium were ST34, with the majority being monophasic (n=120) based on the presence of 213 
only one flagellar H antigen gene copy (antigenic formula: 4,[5],12:i:-) (30). The biphasic S. 214 
Typhimurium (ST36, ST19 and ST34) were associated with infection in 30, 25 and 13 cases, 215 
respectively. Other common serovars included S. Stanley ST29 (62/450, 13.8%), and S. 216 
Weltevreden ST365 (34/450, 7.6%). S. Newport (29/450, 6.4%) consisted of four different STs, 217 
including ST46 (n=22), ST31 (n=5), ST2366 (n=1) and ST2855 (n=1). Other serovars (with at 218 
most 10 cases) included Kentucky (ST198), Bovismorbificans, Rissen, Saintpaul, Virchow, etc. 219 
(Table 2). Furthermore, 34 serovars were detected and associated with a limited number of cases 220 
(1-5 cases). 221 
 222 
The eight most common STs (≥ 10 cases) accounted for ~73% of all NTS and were comprised of  223 
ST34, ST29, ST36, ST365, ST19, ST46, ST11, and ST198. The temporal distribution of the 224 
diarrheal cases caused by these eight STs is shown in Figure 1. In 2015, the absolute number of 225 
NTS cases increased from March and peaked in May and September, followed by a rapid decline. 226 
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 10 
This pattern coincides with the duration of the rainy season in Southern Vietnam (from April to 227 
October). Over time, there was no apparent change in the proportional distribution of NTS 228 
genotypes, with S. Typhimurium (ST34) dominating the epidemiological landscape during our 229 
investigational period. The eight most common STs could be detected throughout the study, with 230 
S. Enteritidis (ST11) and S. Kentucky (ST198) more apparent during periods with more cases.  231 
 232 
High concordance between antimicrobial resistance genotype and phenotype 233 
The majority of NTS were susceptible to imipenem (445/450) and amikacin (447/450); whereas 234 
over half of the collection exhibited resistance to ampicillin and chloramphenicol. Resistance to 235 
ciprofloxacin was comparatively low (39/450), but 221 isolates exhibited reduced susceptibility 236 
to this antimicrobial. Correspondingly, ~58% of the NTS were non-susceptible to ciprofloxacin. 237 
Resistance against trimethoprim-sulfamethoxazole (38%), 3rd generation cephalosporins (13%), 238 
and azithromycin (18%) were comparatively low. Consistent with a high prevalence of resistance, 239 
more than half (53.8%, 242/450) of NTS isolates were determined to be MDR.  240 
 241 
We exploited in silico methods to detect the AMR determinants (acquired genes and mutations) 242 
in all the NTS genomes. The prevalence of all detected AMR genes alongside with their 243 
corresponding antimicrobial classes is shown in Table S1. Subsequently, we assessed how 244 
detected AMR genes (classified by antimicrobial class) could predict phenotypic resistance 245 
(Table 3).   246 
  247 
Quinolone resistance is mediated by mutations in the quinolone resistance determining region 248 
(QRDR; gyrA-83, gyrA-87 and parC-80) and/or the acquisition of plasmid-mediated quinolone 249 
resistance genes (PMQR) (31). At least one QRDR mutation was detected in 38 isolates (8.4%) 250 
(Table S2), leading to nalidixic acid resistance. PMQR were present in around half the collection, 251 
with qnrS1 identified in 47.8% of the isolates (215/450), followed by aac(6’)-lb-cr, qnrS2, qnrB6, 252 
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 11 
qnrD1, oqxAB and patA. The carriage of QRDR mutations and/or PMQR predicted nalidixic acid 253 
resistance with a sensitivity of 96.2% and the specificity of 73.4%. Seven different QRDR 254 
mutations were identified; 11 isolates harbored triple mutations associated with resistance to 255 
ciprofloxacin (Table S2). These organisms included 10 S. Kentucky ST198 (gyrA-S83F, gyrA-256 
D87N, and parC-S80I) and one S. Indiana ST17 (gyrA-S83F, gyrA-D87G, and parC-S80R). 257 
Additionally, ciprofloxacin resistance was associated with the presence of PMQR in either a 258 
single QRDR mutation (n=7) or no mutation (n=20) background (Table S2). The presence of 259 
QRDR mutations and/or PMQR could explain non-susceptibility to ciprofloxacin with 90.8% 260 
sensitivity and 93.2% specificity.  261 
 262 
The most commonly identified -lactamases were blaTEM-95 (58.7%, 264/450) and blaCTX-M-55 263 
(11.6%, 52/450). The presence of -lactamases corresponded with resistance to different -264 
lactams, including ampicillin (97.2% sensitivity, 99.4% specificity), and 3rd generation 265 
cephalosporins (91.2% sensitivity, 99.2% specificity). Resistance to the latter was associated with 266 
blaCTX-M extended-spectrum beta-lactamases (ESBLs) (present in 55/450 isolates). The 267 
carbapenemase blaNDM-1 was present in one S. Typhimurium ST34, but phenotypic testing found 268 
it susceptible to imipenem. Resistance to azithromycin has been reported previously in 269 
Salmonella, and is chiefly attributed to the presence of the macrolide inactivation gene cluster 270 
(mphA-mrx-mphR) within a Salmonella genomic island (SARGI) (32). Herein, 58 NTS isolates 271 
carried the mphA-mrx construct, followed by other less common macrolide resistance genes such 272 
as ermF, ermT, ermB and mefB. A genotype-phenotype comparison demonstrated that the 273 
presence of these genes was in high concordance with macrolide resistance (98.1% specificity).  274 
 275 
Sulphonamide resistance was conferred by sul2, sul3 and sul1, which were present in 237, 116 276 
and 33 of 450 NTS isolates respectively. Resistance to trimethoprim could be explained by 277 
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 12 
dihydrofolate reductase (dfrA) variants, with dfrA12 (97/450) and dfrA14 (69/450) being the most 278 
common. Genotypic prediction for trimethoprim-sulfamethoxazole resistance was calculated by 279 
combining the presence of both sul and dfr genes in each isolate, resulting in high sensitivity 280 
(94.2%) and specificity (98.6%). A large number of aminoglycoside resistance genes was 281 
prevalent, including the aac(3), aac(6), aph and aad families. Each of these is known to confer 282 
resistance to a distinct class of aminoglycosides (Table S1). We observed a high concordance in 283 
genotype-phenotype prediction for gentamicin (Table 3). However, in some instances, the 284 
presence of these genes did not translate to phenotypic resistance. For example, aac(6’)-Iy is 285 
chromosomally encoded and specific to Salmonella, but it is not usually transcribed due to the 286 
absence of an upstream promoter (33). This resulted in the observed genotype-phenotype 287 
mismatch in resistance to amikacin. 288 
 289 
Antimicrobial resistance differs between the major Salmonella sequence types  290 
We proceeded to compare the AMR profiles of the eight most common STs (Figure 2A) in order 291 
to gain insights into potential broader treatment strategies. There was significant variation in the 292 
AMR profile of these major STs. Nearly 80% (149/188) of S. Typhimurium were MDR, with the 293 
majority of the biphasic ST19 and ST36 exhibiting non-susceptibility to four antimicrobial 294 
classes (ampicillin/amoxicillin-clavulanate, chloramphenicol, ciprofloxacin, and co-trimoxazole). 295 
This profile was due to the acquisition of the corresponding blaTEM-95, floR, qnrS1, and dfrA12-sul 296 
(Figure 2B). S. Typhimurium ST34 displayed a more variable AMR profile, with 33.8%, 30.8% 297 
and 14.3% of these organisms non-susceptible to three, four and five antimicrobial classes, 298 
respectively. Noticeably, the presence of blaCTX-M or mphA-mrx was more frequent in ST34 299 
(~25%), resulting to marked increase in the resistance to ceftriaxone and azithromycin, 300 
respectively. A high proportion of MDR was also evident in S. Newport ST46 (59.1%, 13/22) and 301 
S. Kentucky ST198 (70%, 7/10). Half of ST46 (n=11) were non-susceptible to all five classes of 302 
tested antimicrobials, owing to the presence of blaTEM-95, blaCTX-M-55, aac(3)-IIa, aph(6)-Id, 303 
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 13 
aph(3')-Ia, aadA22/24, mphA-mrx, qnrS1, dfrA14-sul3, floR, linG, and arr2/arr3 (Figure 2). S. 304 
Stanley ST29 and S. Weltevreden ST365 were generally susceptible to all classes of 305 
antimicrobials. No AMR determinants were detected in S. Weltevreden ST365, except for two 306 
isolates carrying the chromosomally encoded aac(6)-Iy and qnrS1. 307 
 308 
To explore some additional features of the major NTS genotypes, we sought to compare the 309 
demographic and clinical data associated within the six most prevalent STs. Age was the only 310 
variable with a significant difference among these STs (Kruskal-Wallis test, adjusted p=0.0057), 311 
the median age of children infected with S. Weltevreden ST365 was 4.52 months [IQR 3.48 – 312 
9.4], the lowest among the compared STs. Disease severity factors such as duration of 313 
hospitalization, frequency of diarrhea, and blood neutrophil count were not significantly different 314 
between these six STs (Figure S1). However, we identified two cases in which imipenem was 315 
given as the last resort after unsuccessful recovery with other antimicrobials, and both infections 316 
were caused by MDR S. Newport ST46. The first case was a 7.5-month-old male, who was 317 
treated initially with macrolides and then fluoroquinolones. Imipenem was later administered, and 318 
the patient was hospitalized for 19 days. The second case was a 3-month-old male who was 319 
treated initially with intravenous ceftriaxone and hospitalized for nine days.  320 
 321 
Resistance to first line antimicrobials correlates with disease severity 322 
Treatment regimens was recorded for all enrolled patients, which included ORS, intravenous 323 
rehydration, zinc, probiotics, and antimicrobials. More than 90% of patients were administered 324 
with ORS and zinc supplementation (Table 1). Antimicrobials were also frequently prescribed, 325 
with 92.4% (423/450) of patients receiving empirical antimicrobial treatment following 326 
admission to the hospital and prior to obtaining a microbiological susceptibility test result. Most 327 
of the infected children recovered or had their symptoms improved after three days of enrolment; 328 
the children were discharged from the hospital after a median of five days (IQR 3-7 days) (Table 329 
 o
n
 O
ctober 14, 2020 at University of East Anglia
http://jcm.asm.org/
D
ow
nloaded from
 
 14 
1). Fluoroquinolones were most commonly used for primary treatment (299/423; 70.7%), 330 
followed by 3rd generation cephalosporins (85/423), and macrolides (32/423). These initial 331 
treatments may be changed to a different (secondary or tertiary) antimicrobial, dependent on the 332 
patient’s clinical progression. Such changes occurred in 12.3%, 11.8% and 25% of the 333 
corresponding fluoroquinolone, 3rd generation cephalosporin, and macrolide initial treatments. 334 
For all three scenarios, a change in antimicrobial therapy was significantly associated with a 335 
prolonged hospital stay (Wilcoxon signed-ranked test, p<0.05), possibly reflecting the patients’ 336 
worsening illness or as required for parenterally administered antimicrobial (i.e. ceftriaxone).   337 
 338 
We have previously reported that the NTS MDR status was not associated with hospitalization 339 
duration or clinical outcome (14). As salmonellosis is frequently treated with either 340 
fluoroquinolones, 3rd generation cephalosporins, or macrolides, we stratified the NTS cases by 341 
resistance to these antimicrobials only. For all patients, cases caused by NTS non-susceptible to 342 
more than one of these drug classes had a small but significantly longer hospitalization (pairwise 343 
mean difference: 0.91 day; Wilcoxon signed-rank test, p=0.04) (Figure 3A). This effect was 344 
observed throughout the major NTS STs (Figure 3B). We next sought to understand how the non-345 
susceptibility to the treating agent influences disease recovery (Figure 3C). For patients receiving 346 
initial fluoroquinolone treatment, non-susceptibility to ciprofloxacin was not associated with a 347 
difference in hospitalization time. However, non-susceptibility to ceftriaxone was significantly 348 
associated to a longer hospital stay in children treated with 3rd generation cephalosporins 349 
(Wilcoxon signed-rank test, p=0.028). This effect was also observed with macrolide treatment but 350 
was not significantly different. These observations were not confounded by age as there was no 351 
significant difference in the age of patients receiving these different antimicrobial treatments 352 
(Kruskal-Wallis test, p>0.05). Additionally, we performed the same statistical analyses on the 353 
original full dataset (478 NTS diarrhea cases), which produced analogous results, demonstrating 354 
the robustness of our observations despite the sample size reduction.  355 
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 356 
Discussion 357 
Our study combined a wealth of clinical, microbiological and genomic data to uniquely detail the 358 
characteristics of NTS infections in Southern Vietnam. We found that Salmonella gastroenteritis 359 
exhibits clear seasonality, with the prevalence of disease increasing in May-September. This 360 
pattern has also been recapitulated in NTS surveillance studies in Guangdong, China (34) and 361 
Bangkok, Thailand (35). The incidence rate of dysentery was previously found to be significantly 362 
higher between May and October in Vietnam, particularly for the Southeast region where our 363 
study was conducted (36). This period coincides with the rainy season, with higher precipitation 364 
and humidity, which could grant higher survival and transmissibility of bacterial pathogens in the 365 
environment. This stands in contrast with the seasonal pattern of viral diarrhea, of which the 366 
burden is highest in January to March in Southern Vietnam (13, 37).  367 
 368 
We observed a great diversity of circulating Salmonella, with the monophasic S. Typhimurium 369 
ST34 dominating the NTS epidemiological landscape. This observation resonates with recent 370 
findings elsewhere in Asia, including China (34). The monophasic ST34 is strongly associated 371 
with swine food production (38) and has risen to prominence in Europe and globally during the 372 
last two decades (39). Genomic and phenotypic investigations have suggested that this variant is 373 
ecologically successful due to its extensive repertoire of antimicrobial and heavy metal resistance 374 
genes (30, 40). Indeed, the ST34 isolated from our study show elevated resistance to several 375 
antimicrobials of first line treatments, especially ceftriaxone and azithromycin. We also recently 376 
discovered a novel biphasic, MDR ST34 clone causing invasive diseases in HIV-infected patients 377 
in Vietnam (9, 41). It is therefore of epidemiological interest how this invasive clone is 378 
genetically related to the diarrheagenic ST34 described herein, and such genomic analysis is 379 
being conducted. Other major STs, such as S. Weltevreden ST365, S. Stanley ST29 and S. 380 
Kentucky ST198, have been frequently reported in Asia (34, 42). Similarly to previous reports, 381 
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the majority of S. Stanley (ST29) and S. Weltevreden (ST365) were susceptible to all tested 382 
antimicrobials (19, 34). In contrast, all S. Kentucky (ST198) isolated displayed resistance to 383 
ciprofloxacin and are likely to belong to the Asian expansion of the internationally disseminating 384 
ST198 (43). While S. Enteritidis is predominant in previous surveillances in Greece (44), China 385 
(45), Tunisia (46), USA, and is emerging in Australia, we only documented 17 cases attributed to 386 
this serovar. This discrepancy is explicable due to the younger age of our cohort (median of 9 387 
months-old), as S. Enteritidis has been mainly reported in infections of children > 3 years-old 388 
(34). 389 
    390 
More than half of the isolated NTS were classified as MDR, with particular high non-391 
susceptibility occurrence to commonly prescribed antimicrobials, such as ciprofloxacin. The 392 
major genetic mechanism for resistance was the widespread carriage of qnrS1, which could be 393 
maintained by the sustained use of the antimicrobial locally. Nevertheless, this does not preclude 394 
the importation and local propagation of a pandemic resistant clone, as likely in the case of 395 
ciprofloxacin-resistant ST198 S. Kentucky, or as proven previously for S. sonnei in Vietnam (47). 396 
The high concordance between AMR genotype and phenotype was observed in our collection, 397 
with sensitivity and specificity surpassing 90% for all classes of antimicrobials tested, except for 398 
imipenem, nalidixic acid and azithromycin. Such high genotype-phenotype agreement has been 399 
noted in the Salmonella collection housed in Public Health England, UK (48). However, this 400 
study did not report testing for the aforementioned three antimicrobials. The low sensitivity in 401 
azithromycin non-susceptibility prediction indicates that other resistance mechanisms, such as the 402 
recently determined mutations in acrB (49), remained uncharacterized. Alternatively, the low 403 
specificity in the case of nalidixic acid is likely due to the non-functionality or insufficient 404 
expression of the genetic determinants. These discrepancies warrant further research to improve 405 
the accuracy in inferring AMR phenotypes using sequencing data, which is applicable in public 406 
health surveillances or culture-independent multiplex molecular assay (50).   407 
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 408 
Differing Salmonella STs were not associated with the clinical outcome in our patient cohort. 409 
Clinical severity also did not differ among patients infected with different NTS serogroups in 410 
Thailand (35). However, two patients infected with MDR S. Newport ST46 had to be treated with 411 
the last resort antimicrobial imipenem, showing that tailored antimicrobial treatment remains 412 
crucial in certain scenarios. S. Newport ST46 is infrequently described in Asia and has been 413 
linked to reservoir in reptiles (51). Its pan-resistance and epidemiological ambiguity require 414 
further investigations. Additionally, our analysis indicated that disease recovery may take longer 415 
if the NTS organism was non-susceptible to the treating antimicrobial, particularly for ceftriaxone 416 
and likely azithromycin. Here, NTS infections most commonly occurred in young age group, 417 
particularly children under 1 years-old. These patients presented with many severe clinical 418 
symptoms, including high bloody fecal output, fever, and vomiting, suggesting the highly 419 
infectious and severe nature of this disease. Updated guidelines advise that antimicrobials should 420 
not be used routinely in NTS infections, except for the immunocompromised, the neonates and 421 
the elderly (6, 7, 10). However, antimicrobial treatment should be considered carefully to both 422 
benefit patients with moderate-severe symptoms and to limit the chances of developing 423 
resistance. 424 
 425 
Our observational study was limited to the description of hospitalized cases with mucoid/bloody 426 
diarrhea, NTS was the most common pathogen confirmed by microbiological culturing. 427 
Therefore, other pathogens or cases of co-infection were not analyzed. Also, the burden of NTS 428 
causing milder or acute watery diarrhea was not accounted. As we did not record detailed 429 
epidemiological data (i.e. diet, animal contact, household cases), it was not possible to identify 430 
the possible source of infection. NTS are widely distributed in humans, animals and 431 
environmental reservoirs, so the transmission route may differ case by case. The infections 432 
reported in our study could be either associated with zoonotic transmissions (through the food 433 
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chain/contact with animals) or via sustained human-to-human transmissions distinct from the 434 
animal NTS reservoirs (52, 53). For instance, NTS isolated from asymptomatic close contacts 435 
have been shown to be closely related to ones causing invasive diseases in children in Africa (54). 436 
Our study relied on molecular serotyping (SISTR), without conducting phenotypic serotyping due 437 
to the shortage of trained personnel and dedicated resources. This approach has become attractive 438 
for its high throughput and accurate performance, and produces high concordance between 439 
genotyping and phenotypic serotyping in Shigella flexneri (55). Recently, the web-based 440 
application EnteroBase has independently employed serotype prediction from Salmonella 441 
genomes, which largely produces congruent results with the SISTR outputs (56).  442 
 443 
Conclusions 444 
NTS has become the most common bacterial pathogen detected in children hospitalized with 445 
bloody or mucoid diarrheal diseases in HCMC. S. Typhimurium was the predominant serovar in 446 
this setting and associated with a variety of AMR genes leading to a high rate of MDR in this 447 
serovar. We observed an increasing trend of AMR, especially against the first- and second-line 448 
antimicrobial classes recommended by WHO, i.e. ciprofloxacin, ceftriaxone, azithromycin. 449 
Multi-resistance could lead to prolonged hospitalized duration and the difficulty of choosing 450 
empirical antimicrobials for dysenteric diarrhea. Our work shows that WGS is a powerful method 451 
to characterize the serovar diversity and AMR profiles in NTS. A phylogenetic investigation of 452 
these NTS isolates in the context of global and/or invasive collections is the next step to better 453 
understand transmission dynamics and the evolutionary processes underpinning the circulation of 454 
these organisms. 455 
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 678 
Figure legends 679 
Figure 1. Monthly hospitalization incidence of non-typhoidal Salmonella  680 
Only the eight most common sequence types are visualized. Sequence types that caused fewer 681 
than 10 incidences are grouped together as ‘Other’. 682 
 683 
Figure 2. Antimicrobial resistance in major non-typhoidal Salmonella sequence types 684 
(A) Heat map of antimicrobial resistance phenotype of the eight most common Sequence types. 685 
The left panel displays the proportion of non-susceptibility to 7 classes of tested antimicrobial 686 
agents, including ampicillin/amoxicillin-clavulanate (AMP/AMC); ceftriaxone/ceftazidime 687 
(CRO/CAZ); imipenem (IMP); azithromycin (AZM); ciprofloxacin (CIP); trimethoprim-688 
sulfamethoxazole (SXT) and chloramphenicol (CHL). The right panel displays to proportion of 689 
non-susceptibility to the number of tested antimicrobial classes, including -lactam 690 
(AMP/AMC/CRO/CAZ); IMP; AZM; CIP; SXT and CHL. Isolates were classified as non-691 
susceptible to an antimicrobial class if they were non-susceptible to any agent of that class. The 692 
colour intensity in a cell is proportional to the percentage of non-susceptible NTS isolates to the 693 
tested antimicrobial class. The STs are arranged in decreasing order of prevalence (from top to 694 
bottom). (B) The prevalence of antimicrobial resistance determinants in the eight most common 695 
Sequence types. These determinants are classified by antimicrobial classes, including 3rd 696 
generation cephalosporin (blaCTX-M-14, blaCTX-M-15, blaCTX-M-55), quinolone (qnrS1, qnrS2, qnrB6, 697 
qnrD1, oqxAB, patA, aac(6)-Ib-cr, QRDR mutations), azithromycin (ermB, ermF, ermT, mefB, 698 
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mphA), and co-trimoxazole (sul1/sul2/sul3 + dfrA1/dfrA12/dfrA14/dfrA17/dfrA5). Each bar graph 699 
denotes the proportion of isolates carrying any of these determinants, classified by antimicrobial 700 
class and sequence type.   701 
 702 
Figure 3. Resistance to first line antimicrobials correlated with clinical severity 703 
(A) The hospitalization duration (in days) of all 450 children infected with non-typhoidal 704 
Salmonella, classified by the number of first- and second-line antimicrobials (ciprofloxacin, 705 
ceftriaxone, azithromycin) to which the pathogen was phenotypically non-susceptible, and (B) 706 
further classified by the eight most common sequence types. (C) The hospitalization duration of 707 
NTS infected children who received initial treatment of fluoroquinolone (CIP), 3rd generation 708 
cephalosporin (CRO), or macrolide (AZM), stratified by the pathogen’s non-susceptibility to the 709 
corresponding treating agent (ciprofloxacin, ceftriaxone, azithromycin). The asterisk indicates 710 
statistical significance in the pairwise comparison (Wilcoxon signed-rank test, p< 0.05).  711 
 712 
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1 
 
Table 1. Demographic and clinical manifestations of diarrheal pediatric patients infected with non-
typhoidal Salmonella (N=450). 
Characteristics n % 
Socio-demographic 
  
 
Male 271 60.2 
 
Age in months, median [IQR] 9 6.4-14.9 
Growth a 
  
 
Obese / Overweight / Risk of overweight 100 22.2 
 
Normal 271 63.5 
 
Wasted / Severely wasted 56 12.5 
Clinical symptoms 
  
 
Bloody diarrhea 274 60.9 
 
Mucoid diarrhea 167 37.1 
 
Number of episodes per day, median [IQR] 10 6-10 
 
Dehydration, b 25 5.6 
 
Abdominal pain 115 25.6 
 
Fever (≥37.5°C) at enrolment 294 65.3 
 
Vomit 190 42.2 
Hematology 
  
 
Anemia (Hemoglobin level=70-109g/L) c 148 32.9 
 
Neutrophil count (103/μL), median [IQR] 4.9 3.2-7.2 
 
C-reactive protein (mg/L), median [IQR] 29 11.0-50.0 
Treatment 
  
 
Low-osmolarity oral rehydration solution 418 92.9 
 
IV Rehydration 31 6.9 
 
Antimicrobials 423 94.0 
 
Fluoroquinolones (initial treatment), n (%) 299 70.7 
 
Zinc 412 91.6 
 
Probiotics 300 66.7 
Outcome 
  
 
Hospital stay in days, median [IQR] 5 3-7 
 
Recovered / Improved after 3 days d 393 87.3 
 
Not improved / worse after 3 days 57 12.7 
a Obese: weight for length z score >3SD in children age < 24months; BMI for age z score >3SD in 
children age ≥24months, Overweight: weight for length z score >2SD in children age < 24months; BMI 
for age z score >2SD in children age ≥24months, Wasted: weight for length z score <-2SD in children age 
< 24months; BMI for age z score <-2SD in children age≥24months, Severely wasted: weight for length z 
score <-3SD in children age < 24months); BMI for age z score <-3SD in children age ≥24months 31 
b  All of the dehydrated cases classified as some dehydration according to Integrated Management of 
Childhood Illness 32 
c
 Hemoglobin level cut-off according to World Health Organization guidelines 19 
d
 Defined as “recovered” if patient had <3 passages of loose stool in the 24 hours or “improved” if patient 
had less episodes of diarrhea and less mucus and/or bloody in comparison to the condition of the patient 
at enrolment. 
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Table 2. Non-typhoidal Salmonella predicted serovars isolated from children with diarrheal diseases in 
three tertiary hospitals in Ho Chi Minh City (n=450). Antigenic formula are given in parentheses.  
O-antigen 
group Serovar ST N Serovar ST N 
O:4 (B) 
 
Typhimurium (4,[5],12:i:-)* 34 120 Agona (4:f,g,s:-) 13 4 
Typhimurium (4:i:1,2) 
36 30 Indiana (4:z:1,7) 17 2 
19 25 
Chester (4:e,h:e,n,x) 343 1 
34 13 2063 1 
Stanley (4:d:1,2) 29 62 Schleissheim (4:b:-)  
 
1578 1 
2615 1 2397 1 
Paratyphi B var. Java (4:b:-) 423 7 Saintpaul (4:e,h:1,2) 50 6 135 1 27 2 
Sandiego (4:e,h:e,n,z15) 20 1 
 
  
O:7 (C1) 
 
Rissen (7:f,g:-) 469 9 
Thompson (7:k:1,5) 
 
26 1 
Virchow (7:r:1,2) 
 
359 5 2417 1 
197 1 Ohio (7:b:l,w) 329 1 
Bareilly (7:y:1,5) 
203 4 Mbandaka (7:z10:e,n,z15) 1602 
 
1 
 
909 1 
 
  
O:8  
(C2-C3) 
 
Newport (8:e,h:1,2) 
46 22 Albany (8:z4,z24:-) 292 2 
31 5 Hadar (8:z10:e,n,x) 33 1 
2366 1 Emek (8:g,m,s:-) 76 1 
2855 1 Litchfield (8:l,v:1,2) 214 1 
Kentucky (8:i:z6) 198 10 Muenchen (8:d:1,2) 2424 1 
Bovismorbificans (8:r:1,5) 1499 9 Brunei (8:y:1,5) 2809 1 
Corvallis (8:z4,z23:-) 1541 4   
O:9 (D1) 
 
Enteritidis (9:g,m:-)  11 13 Javiana (9:l,z28:1,5) 
 
2494 3 
74 4 1547 4 
Panama (9:l,v:1,5) 48 1 Dublin (9:g,p:-) 74 1 
O:3,10 
(E1) 
 
Weltevreden (3,10:r:z6) 365 34 Anatum (3,10:e,h:1,6) 64 2 
London (3,10:l,v:1,6) 155 5 Lexington (3,10:z10:1,5) 1542 1 
Give (3,10:l,v:1,7) 516 5 Meleagridis (3,10:e,h:l,w) 3248 1 
Other  
(G, I, K, 
N, O, Q) 
 
Kedougou (13:i:l,w) 1543 3 Johannesburg (40:b:e,n,x) 512 1 
Agbeni (13:g,m:-) 2606 1 Alachua (35:z4,z23:-) 1298 1 
Hvittingfoss (16:b:e,n,x) 446 2 Wandsworth (39:b:1,2) 1498 3 
Orientalis (16:k:e,n,z15) 558 1 subsp. houtenae (43:z4,z23:-) 958 1 
Cerro (18:z4,z23:-) 367 1 subsp. salamae (48:d:z6) 3200 1 
(*): monophasic   
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Table 3. The performance of whole genome sequencing in determine the antimicrobial susceptibility of 
non-typhoidal Salmonella 
 
Antimicrobials Antimicrobial resistance genes 
Phenotype 
Sensitivity 
(%[95%CI]) 
Specificity 
(%[95%CI]) PPV NPV 
Non-
Susceptible 
*  
Susceptible 
ampicillin 
blaTEM-95 / blaOXA-1 / 
bla CARB-3 / 
blaSHV-66 / blaCMY / 
blaCTX-M-55 / blaCTX-M-14 
/ blaCTX-M-15 
yes 279 1 97.2 (94.6-98.8) 99.4 
(96.6-
100) 99.6 95.3 
no 8 162       
ceftriaxone/ 
ceftazidime 
blaCTX-M-55 / blaCTX-M-
14/ 
blaCTX-M-15 
yes 52 3 91.2 (80.7-97.1) 99.2 
(97.8-
99.8) 94.5 98.7 
no 5 390       
imipenem blaNDM-1 
yes 0 1 0.0 (0.0-52.2) 99.8 
(98.8-
100) 0.0 98.9 
no 5 444       
gentamicin aa(3)-IIa / aac(3)-IV / 
aac(6)-IIa 
yes 89 2 100 (95.9-100) 99.4 
(98.0-
99.9) 97.8 100 
no 0 358       
azithromycin mphA / mefB / ermT / 
ermF / ermB 
yes 59 7 72.8 (61.8-82.1) 98.1 
(96.1-
99.2) 89.4 94.3 
no 22 362       
ciprofloxacin 
QRDR$ mutation 
and/or 
PMQR# genes 
yes 236 13 90.8 (86.8-94.0) 93.2 
(88.6-
96.3) 94.8 88.1 
no 24 177       
nalidixic acid QRDR mutation and/or 
PMQR genes 
yes 179 70 96.2 (92.4-98.5) 73.4 
(67.6-
78.6) 71.9 96.5 
no 7 193       
trimethoprim- 
sulfamethoxazole dfr + sul 
yes 163 4 94.2 (89.6-97.2) 98.6 
(96.3-
99.6) 97.6 96.5 
no 10 273       
chloramphenicol  catA1 / catB3 / floR yes 224 2 93.3 
(89.4-
96.1) 99.0 
(96.6-
99.9) 99.1 92.9 
no 16 208       
 
(*): Fully resistance and intermediate resistance are included as non-susceptible. 
($): Quinolone resistance determining region (QRDR): gyrA-83 + gyrA-87 + parC-80  
(#): Plasmid-mediated Quinolone Resistance genes (PMQR): qnrB6/ qnrD1/ qnrS1/ qnrS2/ oqx_AB/ 
patA/ aac(6)-Ib-cr 
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